GSA Capital Partners LLP Cuts Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

GSA Capital Partners LLP trimmed its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 62.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,966 shares of the company’s stock after selling 8,139 shares during the period. GSA Capital Partners LLP’s holdings in Omnicell were worth $217,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Federated Hermes Inc. boosted its holdings in Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after buying an additional 909,480 shares during the last quarter. Pacer Advisors Inc. raised its holdings in shares of Omnicell by 32.6% during the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after acquiring an additional 508,789 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Omnicell by 61.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after buying an additional 228,093 shares during the period. Liontrust Investment Partners LLP purchased a new position in Omnicell in the second quarter worth approximately $4,066,000. Finally, Vanguard Group Inc. increased its position in shares of Omnicell by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after purchasing an additional 80,312 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday. Craig Hallum increased their target price on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Barclays boosted their price target on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Bank of America reiterated a “neutral” rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Finally, StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $52.00.

Omnicell Stock Up 3.6 %

Shares of Omnicell stock opened at $45.69 on Monday. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74. The firm has a market capitalization of $2.12 billion, a P/E ratio of -117.15, a P/E/G ratio of 37.10 and a beta of 0.81. The firm’s 50 day moving average is $44.27 and its two-hundred day moving average is $37.41.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.